Risk Level: LowOral CapsuleSubQ InjectTopical
KPV
Targeted NF-κB Nuclear Blockade & Gastrointestinal Mucosal Anti-Inflammation
Aliases / Trademarks: Lys-Pro-Val · Alpha-MSH(11-13)
A potent C-terminal tripeptide fragment of alpha-MSH (Lys-Pro-Val). Operates without steroid side effects, penetrating cell nuclei to directly shut down NF-κB inflammatory cytokine cascades in ulcerative colitis, leaky gut, and chronic inflammatory tissue.
Associated Protocol Category: View Protocol Roadmap
⏱️ Real-World Expectation & Sentiment Timeline
Day 1 - 3：Gut Mucosal Quenching Phase Core Milestones
Abdominal cramping, bloating, and spasm noticeably ease; bowel movements become firmer and better formed
Stage Critical Guidance:Oral enteric-coated capsules are the top choice for intestinal conditions.
Standard Dosage & Administration Guidelines
Typical Dose
200mcg - 500mcg / dose
Frequency
1 - 2 times daily
Cycle Length
4 - 6 weeks per course
Clinical & Community Notes: Enteric-coated capsules are preferred for digestive inflammation, while SubQ injections target systemic joints and dermatologic conditions.
Titration Schedule & Dosing Decision Tree
Step-up ProtocolStarting & Maintenance Criteria:250mcg once daily
Maintain for 4 consecutive weeks
Titration & Adjustment Rules:For severe active flare-ups, increase to 500mcg twice daily
| Timeline | Dosage & Frequency | Objective | Key Biomarkers / Checks |
|---|---|---|---|
| Weeks 1 - 4 | 250mcg - 500mcg 1-2 times daily | Systemic resolution of intestinal and tissue chronic inflammation | Abdominal pain incidence, stool consistency |
Educational Composite Scenarios
1 Composite Archetypesℹ️ Names, timelines, doses, lab values, and outcomes are illustrative composites. They are not actual patient records or treatment recommendations.
8-Week KPV Peptide Protocol: Ulcerative Colitis Mucosal Healing & Calprotectin Normalization
👤 Composite Profile: Male, 29yo, 3-year history of ulcerative colitis with 4-5 daily loose/bloody stools and multiple food intolerances.
Illustrative Protocol: KPV enteric-coated oral capsules (500mcg BID on empty stomach) co-administered with oral BPC-157 (500mcg daily).
Illustrative Timeline:
Week 1Bowel Frequency 5x -> 3x
Cramping decreased substantially by Day 4; mucus in stool disappeared.
Week 4Hematochezia Completely Resolved
Formed stools restored with zero hematochezia; healthy weight regained (+2.5kg).
Week 8Fecal Calprotectin 38 ug/g
Lab retest showed Calprotectin dropped to 38 ug/g, confirming full mucosal barrier integrity.
Scenario Outcome and Learning Points: Achieved complete clinical mucosal remission with Calprotectin dropping from 480 to 38 ug/g.
💡 Educational Takeaway: KPV directly deactivates epithelial NF-κB inflammation. Always use enteric-coated capsules for lower GI mucosal targeting.
Visual Syringe Reconstitution Calculator
Accurately calculate vial reconstitution concentration and U-100 syringe units
Syringe:
Quick Clinical & Community Presets:
mg
ml
mcg
Syringe Pull To Mark
10Units (Ticks on Syringe)
Equal to 0.100 ml fluid | Yields 20 doses
Conc: 2.50 mg/ml
💉 Visual Needle Simulation (U-100 Standard)Target: 10 / 100 U
① Dissolution Technique: Slowly slide BAC water down the vial wall. Never shake vigorously to protect peptide chains.
② Cold-Chain Storage: Store reconstituted liquid at 2-8°C away from light. Best used within 28-30 days.
③ Standard Syringe: Calculation based on U-100 insulin syringes (100 units = 1.0 ml).
Evidence-Based FAQs & Reddit Theoretical Mythbusters
Verified biochemical mechanisms, category physiology, and Reddit misconception clarity
1. Compound-Specific Dilemmas & Solutions
🔗 Synergistic Stacking Protocols (Synergies)
Synergy Stack
+ BPC-157
BPC-157 rebuilds mucosal architecture while KPV suppresses inflammatory cascades—the ultimate gut-healing pair.
📊 Educational Composite Scenarios (1)
Illustrative 6-16 week timelines, sample biomarker metrics, and educational protocol takeaways for KPV.
ℹ️ Names, timelines, doses, lab values, and outcomes are illustrative composites. They are not actual patient records or treatment recommendations.
Textbook ResponderMale, 29 y/o•8 Weeks Protocol
8-Week KPV Peptide Protocol: Ulcerative Colitis Mucosal Healing & Calprotectin Normalization
Illustrative Protocol: KPV enteric-coated oral capsules (500mcg BID on empty stomach) co-administered with oral BPC-157 (500mcg daily).
Fecal Calprotectin
38 ug/g ()
-92.1% (Mucosal Remission)
Daily Stool Frequency
1 - 2
Zero Blood / Normal Stool
Dietary Tolerance
Reported change
Eliminated Food Allergies
Illustrative Weekly Highlights:
Week 1Cramping decreased substantially by Day 4; mucus in stool disappeared.
Week 4Formed stools restored with zero hematochezia; healthy weight regained (+2.5kg).
Week 8Lab retest showed Calprotectin dropped to 38 ug/g, confirming full mucosal barrier integrity.
💡 Educational Takeaway: KPV directly deactivates epithelial NF-κB inflammation. Always use enteric-coated capsules for lower GI mucosal targeting.
Inspect Full Scenario Dossier →Dedicated Dose & Syringe Calculator
💉 KPV Reconstitution & Syringe Tick Tool
Standard vial size: 5mg. Recommended BAC water: 2ml. Typical dose: 200mcg - 500mcg / dose.
Visual Syringe Reconstitution Calculator
Accurately calculate vial reconstitution concentration and U-100 syringe units
Syringe:
Quick Clinical & Community Presets:
mg
ml
mcg
Syringe Pull To Mark
10Units (Ticks on Syringe)
Equal to 0.100 ml fluid | Yields 20 doses
Conc: 2.50 mg/ml
💉 Visual Needle Simulation (U-100 Standard)Target: 10 / 100 U
① Dissolution Technique: Slowly slide BAC water down the vial wall. Never shake vigorously to protect peptide chains.
② Cold-Chain Storage: Store reconstituted liquid at 2-8°C away from light. Best used within 28-30 days.
③ Standard Syringe: Calculation based on U-100 insulin syringes (100 units = 1.0 ml).
Evidence Context and Common Questions
KPV Key TakeawaysResearch References
References may include preclinical or clinical research and do not establish safety, efficacy, or dosing for an individual.
The anti-inflammatory peptide alpha-MSH and its C-terminal tripeptide KPV
Cellular and Molecular Life Sciences · 2008